WH Names 10 Meds Subject To Medicare Negotiations

Reuters reports:

The Biden administration on Tuesday released its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people, with big-selling blood thinner Eliquis from Bristol Myers Squibb.

President Joe Biden’s signature Inflation Reduction Act (IRA), signed into law last year, allows the Medicare health program for Americans aged 65 and over to negotiate prices for some of its most costly drugs.

Medicines on the list include Merck & Co’s diabetes drug Januvia, Eliquis rival Xarelto from Johnson & Johnson, and AbbVie’s leukemia treatment Imbruvica. Other drugs on the list include Amgen’s rheumatoid arthritis drug Enbrel, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, J&J’s arthritis and Crohn’s disease Stelara and insulin from Novo Nordisk.

Read the full article.

The Biden administration on Tuesday released its list of 10 prescription medicines including blood thinner Eliquis from Bristol Myers Squibb and Pfizer that will be subject to the first-ever price negotiations by the Medicare health program. https://t.co/1C9nNvUxO2

— Reuters Health (@Reuters_Health) August 29, 2023

Biden administration unveils first 10 drugs subject to Medicare price negotiations. For FIRST time in history of Medicare the federal govt can negotiate lower prices for prescription drug prices. This was all President Biden and the Dems! https://t.co/YKzTBR4ytS

— (((DeanObeidallah))) (@DeanObeidallah) August 29, 2023